Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance

Aug. 24, 2022 1:32 PM ETIntegra LifeSciences Holdings Corporation (IART)By: Dania Nadeem, SA News Editor

PRODUCT RECALLED, DEFECTIVE PRODUCT Stamped Cardboard Boxes, Soft Lighting

Matt Molloy/iStock via Getty Images

  • Integra LifeSciences Holdings (NASDAQ:IART) said the U.S. Food and Drug Administration and other regulatory authorities outside the United States, initiated a voluntary global removal of all CereLink intracranial pressure monitors as customers reported that the monitors pressure readings were out of range.
  • As a result of the voluntary action, the company cuts its third quarter and full-year revenue and profit guidance.
  • The company believes that the out-of-range readings were caused by electrical interference from the external environment and/or interference from a component on the circuit board of the monitor.
  • The company said these out-of-range readings have occurred at a low incidence rate and at a limited number of sites, and it had decided to remove all CereLink monitors from the field.
  • The company now expects third quarter revenue to be between $374M to $382M ($387.79M consensus) from prior guidance of $383M to $391M. Q3 Profit to be between $0.69 to $0.73 from earlier guidance of $78 to $0.82. ($0.80 consensus)
  • The company sees full year revenue to be between $1.548B to $1.566B from a range of $1.557B to $1.575B vs consensus estimate of $1.57B.
  • Full year profit guidance to a range of $3.12 to $3.20 from $3.21 to $3.29 vs consensus estimate of $3.24.
  • (IART) stock is down 4.3%.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.